Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in CBF-AML Refractory or in Molecular Relapse
NCT02113319Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Apr 2007
- Primary completion
- May 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute myeloid leukemia (AML), sponsored by Centre Hospitalier Universitaire d'Angers. Started Apr 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02113319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02113319.